Summit Therapeutics plc Stock

Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over

Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according

On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest

New York City-based Summit Street Capital Management increased its stake in Core Natural Resources (NYSE:CNR) by 81,170 shares in the third quarter, adding approximately $10.4 million in position

New York City-based Summit Street Capital Management fully exited its position in Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC), reducing holdings by 281,812 shares during the quarter and

Did you know that Summit Therapeutics (NASDAQ: SMMT) is one of the few publicly traded companies that has a market cap of more than $10 billion, but no revenue? With that kind of a valuation and

Sometimes, everything can seem to be going your way. And then the wheels fall off. That's the situation Summit Therapeutics (NASDAQ: SMMT) finds itself in.

Shares of the clinical-stage biotech

It's not possible to go back in time and invest in Nvidia or Amazon when they were still relatively small companies. However, it is possible to identify corporations that appear poised to establish

The wave of crypto optimism we've seen this year hasn't done much for Cardano (CRYPTO: ADA). The smart contract crypto's price is down 50% year over year and, at $0.41, is worth about 86% less than

The U.S. stock market turned sharply lower Tuesday morning in reaction to seemingly negative comments by the CEOs of Morgan Stanley (NYSE: MS) and Goldman Sachs (NYSE: GS). At the Global Financial

What if you had invested in any of the current leaders in the biotech industry before they established themselves as such? You'd have earned terrific returns. While we can't go back in time to do

Explore the exciting world of Summit Therapeutics (NASDAQ: SMMT) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights

Summit Financial Wealth Advisors, LLC initiated a new position in First Trust Enhanced Short Maturity ETF (NASDAQ:FTSM), acquiring approximately $20.03 million in shares as of Q3 2025, according to

Even in hindsight, it would have been difficult to predict Summit Therapeutics' (NASDAQ: SMMT) exceptional rise over the past three years. The company's shares have skyrocketed by more than 1,500%

Summit Financial Wealth Advisors, LLC established a new position in Lockheed Martin(NYSE:LMT), acquiring 12,393 shares valued at approximately $5.74 million as of the second quarter ended June 30

Shares of Earth-imaging satellites company BlackSky Technology (NYSE: BKSY) soared 13.5% through 3 p.m. ET Thursday -- probably because of a couple of tweets posted on X announcing BlackSky's plans

A rocky road for Summit Therapeutics got a lot rougher over the weekend. The company presented somewhat disappointing data for the experimental cancer drug it's developing.

When the market opened on

We're well into the home stretch of 2025. August is more than halfway over. But there's still plenty of time remaining in the year -- and in this month -- to invest in stocks that hold the potential

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially

Three years ago, Summit Therapeutics (NASDAQ: SMMT) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time

Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others

One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (NASDAQ: SMMT) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped

An analyst's downbeat new take on Summit Therapeutics (NASDAQ: SMMT) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors